BioVentrix has announced the appointment of Serjan D Nikolic as vice president of therapy development. In his new role, Nikolic will focus on the clinical implementation of the company’s existing surgical and future transcatheter product lines for less-invasive ventricular enhancement known as the less-invasive ventricular enhancement therapy (LIVE) procedure. Additionally, he will spearhead development of regulatory strategy for a forthcoming submission to FDA.
According to a press release, Nikolic brings more than 35 years of combined industry and academic medical research experience to BioVentrix. Most recently, he was co-founder and chief technology officer at CardioKinetix, a medical device company focused on developing transcatheter therapies for the treatment of heart failure. Previously, he served as vice president of medical affairs for Neovasys, an angiogenic therapy medical device company pioneering the use of implant material to promote new blood vessel formation. His other industry experience has included co-founder and management positions at CardioSynopsys, Advance Closure Systems, and Somnus.
“I am very excited to join the BioVentrix team and to have an active role in development of new therapy options for patients who suffer from heart failure post-myocardial infarction,” says Nikolic. “Despite the great advances in devices and pharmacological therapy, the prevalence and incidence of this disease looms as a new epidemic in cardiovascular medicine. The robust new technology from BioVentrix is promising for treating a wide range of patients, especially with advent of the new hybrid transcatheter–minimally invasive approach.”